stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments.
Roberto VisintaineriD, Anna FochesatoiD, Daniele BoarettiiD, Stefano GiampiccoloiD, Shayne Watson, Micha Levi, Federico RealiiD, Luca MarchettiiD
Abstract
IntroductionTuberculosis (TB) poses a significant threat to global health, with millions of new infections and approximately one million deaths annually. Various modeling efforts have emerged, offering tailored data-driven and physiologically-based solutions for novel and historical compounds. However, this diverse modeling panorama may lack consistency, limiting result comparability. Drug-specific models are often tied to commercial software and developed on various platforms and languages, potentially hindering access and complicating the comparison of different compounds. MethodsThis work introduces stormTB: SimulaTOr of a muRine Minimal-pbpk model for anti-TB drugs. It is a web-based interface for our minimal physiologically based pharmacokinetic (mPBPK) platform, designed to simulate custom treatment scenarios for tuberculosis in murine models. The app facilitates visual comparisons of pharmacokinetic profiles, aiding in assessing drug-dose combinations. ResultsThe mPBPK model, supporting 11 anti-TB drugs, offers a unified perspective, overcoming the potential inconsistencies arising from diverse modeling efforts. The app, publicly accessible, provides a user-friendly environment for researchers to conduct what-if analyses and contribute to collective TB eradication efforts. The tool generates comprehensive visualizations of drug concentration profiles and pharmacokinetic/pharmacodynamic indices for TB-relevant tissues, empowering researchers in the quest for more effective TB treatments. stormTB is freely available at the link: https://apps.cosbi.eu/stormTB.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.64
- Field percentile
- top 41%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs
Joseph M. Cicchese, Awanti Sambarey, … Sriram Chandrasekaran·Scientific ReportsPeer-reviewed·Mar 11, 2021
- Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approach
Niurys de Castro Suarez, Eric L. Nuermberger, … Radojka M. Savić·bioRxiv·Feb 2, 2026
- Optimizing tuberculosis treatment efficacy: comparing the standard regimen with Moxifloxacin-containing regimens
M. Budak, J. M. Cicchese, … D. E. Kirschner·bioRxiv·Dec 18, 2022
- Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework
Sylvie Sordello, Alessia Tagliavini, … Anna M. Upton·bioRxiv·May 7, 2026
- Predicting the Outcomes of New Short-Course Regimens for Multi-Drug Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modelling
Tan Nhut Doan, Pengxing Cao, … Emma Sue McBryde·Antimicrobial Agents and ChemotherapyPeer-reviewed·Sep 24, 2018
- Use of Multiple Pharmacodynamic Measures to Deconstruct the Nix-TB Regimen in a Short-Course Murine Model of Tuberculosis
M. A. Lyons, A. Obregon-Henao, … G. T. Robertson·bioRxiv·Nov 8, 2023